Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Dr. Joshua Sabari, a professor at New York University's Department of Medicine, has recently spoken about the different treatment options for ALK-positive non-small cell lung cancer (NSCLC). Specifically, he discussed…
According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…
.jpg)
A recent article in Northwestern's University Health reported that although the survival rate for cancer patients has vastly improved over the past twenty years, the deaths due to metastatic cancer…
.jpg)
A recent article published in Curetoday highlights not only the many new and successful therapies available to cancer patients but it also illustrates how patients can connect to other…
Pattern.Org Pattern.org was created by the Rare Cancer Research Foundation, a nonprofit dedicated to improving the lives of rare cancer patients by accelerating research. Pattern.org specifically, is a branch of…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
